News Archive
May 2022
Alentis TherapeuticsAlentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
May 2022
Engimmune TherapeuticsEngimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-Cell Receptor Therapeutics
April 2022
AM-Pharma400 Patients Have Been Enrolled an AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-Associated Acute Kidney Injury
April 2022
Acrivon TherapeuticsAcrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives
April 2022
Araris BiotechAraris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 2022
ImCheck TherapeuticsImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
March 2022
Lava TherapeuticsLAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
February 2022
Hummingbird BioscienceHummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
February 2022
ImCheck TherapeuticsImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 2022
Lava TherapeuticsLAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
February 2022
ImCheck TherapeuticsFor the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
January 2022
ImCheck TherapeuticsImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
January 2022
Alentis TherapeuticsAlentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
December 2021
Acrivon TherapeuticsAcrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
December 2021
Hummingbird BioscienceHummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
November 2021
Hummingbird BioscienceHummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
November 2021
Lava TherapeuticsLAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 2021
ImCheck TherapeuticsImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 2021
Pureos BioventuresPureos Bioventures Invests in Acrivon Therapeutics
November 2021
Araris BiotechAraris is Expanding its Scientific Advisory Board with Dr. Jeff Sharman and Dr. Clive Stanway
November 2021
Hummingbird BioscienceHummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
November 2021
Pureos BioventuresPureos Bioventures Welcomes Dr. Lars Nieba to its Team as Venture Partner
November 2021
Alentis TherapeuticsAlentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaele Tordjman as Chairperson
October 2021
Hummingbird BioscienceHummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
October 2021
ImCheck TherapeuticsImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 2021
Lava TherapeuticsLAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
October 2021
Hummingbird BioscienceHummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers
September 2021
Hummingbird BioscienceHummingbird Bioscience Opens New Office and Research Facilities
September 2021
Pureos BioventuresPureos Bioventures Expands the Team by the Appointment of Venture Partners
September 2021
ImCheck TherapeuticsImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 2021
Araris BiotechAraris Biotech Shortlisted in Top 5 of World ADC Awards 2021 in Category “Best ADC Platform Technology“
September 2021
Hummingbird BioscienceHummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
September 2021
ImCheck TherapeuticsImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 2021
Araris BiotechAraris Biotech Ranks TOP11 at Swiss Startup Award 2021
September 2021
AM-PharmaAM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
August 2021
Lava TherapeuticsLAVA Therapeutics Provides Business Update and Reports Second Quarter Results
August 2021
EyevensysEyevensys Raises $12M in a Series B Plus Funding Round
July 2021
Alentis TherapeuticsAlentis Therapeutics Raises USD 67 Million in Series B Financing
July 2021
Lava TherapeuticsLAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
July 2021
ImCheck TherapeuticsImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
July 2021
AM-PharmaAM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
July 2021
AM-PharmaAM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
June 2021
Corlieve TherapeuticsuniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
May 2021
Hummingbird BioscienceHummingbird Bioscience Raises US$125 Million in Series C Financing
April 2021
ImCheck TherapeuticsImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 2021
Pureos BioventuresPureos Bioventures Expands Fund Size to USD 205 Million